LINC00426, a novel m6A-regulated long non-coding RNA, induces EMT in cervical cancer by binding to ZEB1.

[1]  Y. Li,et al.  Managing Cancer Drug Resistance from the Perspective of Inflammation , 2022, Journal of oncology.

[2]  Qiaojun He,et al.  Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. , 2022, European journal of pharmacology.

[3]  Jinghan Zhu,et al.  Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma , 2022, Aging.

[4]  Hui Hu,et al.  Knockdown of lncRNA FOXD2-AS1 Inhibits Proliferation, Migration, and Drug Resistance of Breast Cancer Cells , 2021, Computational and mathematical methods in medicine.

[5]  J. Ding,et al.  Increased ATG5 Expression Predicts Poor Prognosis and Promotes EMT in Cervical Carcinoma , 2021, Frontiers in Cell and Developmental Biology.

[6]  M. Fan,et al.  LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[7]  Shaoyun Chen,et al.  m6A methyltransferase METTL3-mediated lncRNA FOXD2-AS1 promotes the tumorigenesis of cervical cancer , 2021, Molecular therapy oncolytics.

[8]  Zhi-wei Wang,et al.  METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE , 2021, Molecular therapy oncolytics.

[9]  Guanbin Song,et al.  Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT , 2021, Journal of experimental & clinical cancer research : CR.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  Ling Wei,et al.  Noncoding RNAs in gastric cancer: implications for drug resistance , 2020, Molecular Cancer.

[12]  Jacques Ferlay,et al.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis , 2019, The Lancet. Global health.

[13]  Q. Kan,et al.  The interplay between m6A RNA methylation and noncoding RNA in cancer , 2019, Journal of Hematology & Oncology.

[14]  M. Najafi,et al.  Cancer stem cell (CSC) resistance drivers. , 2019, Life sciences.

[15]  S. Jaffrey,et al.  Reading, writing and erasing mRNA methylation , 2019, Nature Reviews Molecular Cell Biology.

[16]  Jie Shen,et al.  LncRNA XIST promotes pancreatic cancer migration, invasion and EMT by sponging miR-429 to modulate ZEB1 expression. , 2019, The international journal of biochemistry & cell biology.

[17]  Fan Mo,et al.  The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1α , 2019, Cell Death & Differentiation.

[18]  Qifeng Yang,et al.  LncRNA–CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA‐215 , 2018, Journal of cellular physiology.

[19]  Yu-Sheng Chen,et al.  Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism , 2018, Cell Research.

[20]  Mohini Singh,et al.  EMT: Mechanisms and therapeutic implications , 2017, Pharmacology & therapeutics.

[21]  Longhua Chen,et al.  A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1 , 2017, Journal of Hematology & Oncology.

[22]  A. Tramontano,et al.  The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition , 2016, Oncogene.

[23]  S. Dhamija,et al.  From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis , 2016, International journal of cancer.

[24]  S. Alahari,et al.  Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications , 2016, Molecular Cancer.

[25]  M. Ibrahim,et al.  Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp , 2015, Cancer Cell International.

[26]  Rajvir Dahiya,et al.  Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. , 2015, Cancer research.

[27]  Li-juan Wang,et al.  LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer , 2015, Oncotarget.

[28]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[29]  Yongzhan Nie,et al.  Long Noncoding RNA MRUL Promotes ABCB1 Expression in Multidrug-Resistant Gastric Cancer Cell Sublines , 2014, Molecular and Cellular Biology.

[30]  Udo Schumacher,et al.  Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds , 2013, Molecular Cancer.

[31]  Howard Y. Chang,et al.  Control of somatic tissue differentiation by the long non-coding RNA TINCR , 2012, Nature.

[32]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[33]  C. Ponting,et al.  Evolution and Functions of Long Noncoding RNAs , 2009, Cell.

[34]  S. Coughlin,et al.  Burden of cervical cancer in the United States, 1998–2003 , 2008, Cancer.

[35]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[36]  J. Massagué,et al.  Epithelial-Mesenchymal Transitions Twist in Development and Metastasis , 2004, Cell.